CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of dry eye syndrome
3.4.1.2. Increase in screen time and rise in adoption of contact lens
3.4.1.3. Upsurge in geriatric population
3.4.2. Restraints
3.4.2.1. Lack of awareness about dry eye syndrome
3.4.3. Opportunities
3.4.3.1. Latest product approvals and high untapped market potential
CHAPTER 4: DRY EYE SYNDROME TREATMENT MARKET, BY DRUG
4.1. Overview
4.1.1. Market size and forecast
4.2. Lubricant
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Dry eye syndrome drugs
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM
5.1. Overview
5.1.1. Market size and forecast
5.2. Eye drops
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Ointments
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Other
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Retail pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: DRY EYE SYNDROME TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Drug
7.2.3. Market size and forecast, by Dosage form
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Drug
7.2.5.1.2. Market size and forecast, by Dosage form
7.2.5.1.3. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Drug
7.2.5.2.2. Market size and forecast, by Dosage form
7.2.5.2.3. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Drug
7.2.5.3.2. Market size and forecast, by Dosage form
7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Drug
7.3.3. Market size and forecast, by Dosage form
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Drug
7.3.5.1.2. Market size and forecast, by Dosage form
7.3.5.1.3. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Drug
7.3.5.2.2. Market size and forecast, by Dosage form
7.3.5.2.3. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Drug
7.3.5.3.2. Market size and forecast, by Dosage form
7.3.5.3.3. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Drug
7.3.5.4.2. Market size and forecast, by Dosage form
7.3.5.4.3. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Drug
7.3.5.5.2. Market size and forecast, by Dosage form
7.3.5.5.3. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Drug
7.3.5.6.2. Market size and forecast, by Dosage form
7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Drug
7.4.3. Market size and forecast, by Dosage form
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Market size and forecast, by Drug
7.4.5.1.2. Market size and forecast, by Dosage form
7.4.5.1.3. Market size and forecast, by Distribution Channel
7.4.5.2. Japan
7.4.5.2.1. Market size and forecast, by Drug
7.4.5.2.2. Market size and forecast, by Dosage form
7.4.5.2.3. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Drug
7.4.5.3.2. Market size and forecast, by Dosage form
7.4.5.3.3. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Drug
7.4.5.4.2. Market size and forecast, by Dosage form
7.4.5.4.3. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Drug
7.4.5.5.2. Market size and forecast, by Dosage form
7.4.5.5.3. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Drug
7.4.5.6.2. Market size and forecast, by Dosage form
7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Drug
7.5.3. Market size and forecast, by Dosage form
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Drug
7.5.5.1.2. Market size and forecast, by Dosage form
7.5.5.1.3. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Drug
7.5.5.2.2. Market size and forecast, by Dosage form
7.5.5.2.3. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Drug
7.5.5.3.2. Market size and forecast, by Dosage form
7.5.5.3.3. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Drug
7.5.5.4.2. Market size and forecast, by Dosage form
7.5.5.4.3. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. AbbVie Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Viatris Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Novartis AG
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Bausch Health Companies Inc
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Sun Pharmaceutical Industries Ltd.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Novaliq
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Key strategic moves and developments
9.7. Santen Pharmaceutical Co., Ltd.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. AFT Pharmaceuticals Limited
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Alcon
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Johnson & Johnson (J&J)
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
TABLE 01. GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 02. DRY EYE SYNDROME TREATMENT MARKET FOR LUBRICANT, BY REGION, 2022-2032 ($MILLION)
TABLE 03. DRY EYE SYNDROME TREATMENT MARKET FOR DRY EYE SYNDROME DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. DRY EYE SYNDROME TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 06. DRY EYE SYNDROME TREATMENT MARKET FOR EYE DROPS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. DRY EYE SYNDROME TREATMENT MARKET FOR OINTMENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. DRY EYE SYNDROME TREATMENT MARKET FOR OTHER, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 10. DRY EYE SYNDROME TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 11. DRY EYE SYNDROME TREATMENT MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 12. DRY EYE SYNDROME TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. DRY EYE SYNDROME TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA DRY EYE SYNDROME TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 18. U.S. DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 19. U.S. DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 20. U.S. DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. CANADA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 22. CANADA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 23. CANADA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 24. MEXICO DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 25. MEXICO DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 26. MEXICO DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 27. EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 28. EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 29. EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 30. EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 31. GERMANY DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 32. GERMANY DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 33. GERMANY DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. FRANCE DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 35. FRANCE DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 36. FRANCE DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 37. UK DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 38. UK DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 39. UK DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 40. ITALY DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 41. ITALY DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 42. ITALY DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 43. SPAIN DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 44. SPAIN DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 45. SPAIN DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 53. CHINA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 54. CHINA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 55. CHINA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 56. JAPAN DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 57. JAPAN DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 58. JAPAN DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 59. INDIA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 60. INDIA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 61. INDIA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 71. LAMEA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 72. LAMEA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 73. LAMEA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 74. LAMEA DRY EYE SYNDROME TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 75. BRAZIL DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 76. BRAZIL DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 77. BRAZIL DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 87. ABBVIE INC.: KEY EXECUTIVES
TABLE 88. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 89. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 90. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 91. ABBVIE INC.: KEY STRATERGIES
TABLE 92. VIATRIS INC.: KEY EXECUTIVES
TABLE 93. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 94. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 95. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 96. VIATRIS INC.: KEY STRATERGIES
TABLE 97. NOVARTIS AG: KEY EXECUTIVES
TABLE 98. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 99. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 100. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 101. BAUSCH HEALTH COMPANIES INC: KEY EXECUTIVES
TABLE 102. BAUSCH HEALTH COMPANIES INC: COMPANY SNAPSHOT
TABLE 103. BAUSCH HEALTH COMPANIES INC: PRODUCT SEGMENTS
TABLE 104. BAUSCH HEALTH COMPANIES INC: PRODUCT PORTFOLIO
TABLE 105. BAUSCH HEALTH COMPANIES INC: KEY STRATERGIES
TABLE 106. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 107. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 108. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 109. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 110. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 111. NOVALIQ: KEY EXECUTIVES
TABLE 112. NOVALIQ: COMPANY SNAPSHOT
TABLE 113. NOVALIQ: PRODUCT SEGMENTS
TABLE 114. NOVALIQ: PRODUCT PORTFOLIO
TABLE 115. NOVALIQ: KEY STRATERGIES
TABLE 116. SANTEN PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
TABLE 117. SANTEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 118. SANTEN PHARMACEUTICAL CO., LTD.: PRODUCT SEGMENTS
TABLE 119. SANTEN PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 120. SANTEN PHARMACEUTICAL CO., LTD.: KEY STRATERGIES
TABLE 121. AFT PHARMACEUTICALS LIMITED: KEY EXECUTIVES
TABLE 122. AFT PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
TABLE 123. AFT PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
TABLE 124. AFT PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
TABLE 125. ALCON: KEY EXECUTIVES
TABLE 126. ALCON: COMPANY SNAPSHOT
TABLE 127. ALCON: PRODUCT SEGMENTS
TABLE 128. ALCON: PRODUCT PORTFOLIO
TABLE 129. JOHNSON & JOHNSON (J&J): KEY EXECUTIVES
TABLE 130. JOHNSON & JOHNSON (J&J): COMPANY SNAPSHOT
TABLE 131. JOHNSON & JOHNSON (J&J): PRODUCT SEGMENTS
TABLE 132. JOHNSON & JOHNSON (J&J): PRODUCT PORTFOLIO
